New antibody may improve diagnosis of prostate cancer
Prostate cancer is the most frequently diagnosed malignancy in adult men in the developed world. Even if diagnosed and treated early, prostate cancer may progress to aggressive castrate-resistant prostate cancer. In fact, prostate cancer is the second leading cause of cancer-related death in men in certain countries. One reason that makes prostate cancer hard to treat is that prostate cancer is highly heterogeneous.
Recently, Roche announced that a monoclonal primary antibody, SP116, could improve the diagnosis of prostate cancer. This antibody recognizes certain parts of the protein AMACR. AMACR, or alpha-methylacyl-CoA racemase, is an enzyme that is found in mitochondria and peroxisomes in cells. In peroxisomes, AMACR is involved in the breakdown of a fatty acid called pristanic acid; in mitochondria, AMACR further breaks down the molecules derived from pristanic acid. Deficiency in AMACR may cause many neurological problems. In prostate adenocarcinoma, AMACR is often elevated, making it a biomarker for the disease.
The new antibody SP116 is effective in diagnosing prostate cancer, when used in combination with the VENTANA Basal Cell Cocktail, which detects two proteins called 34ßE12 and p63. This new diagnostic approach requires less tissue samples in comparison with traditional methods. The SP116-VENTANA cocktail might improve diagnosis as well survival of prostate cancer.
Prostate cancer accounts for about 30% of all cancer diagnoses in American men. It is imperative to develop ways to reduce morbidity and mortality from the disease. (Cusabio offers polyclonal antibody.)